Furthermore, the use of statins has been reported to reduce the efflux activity of drug transporters Pgp/ABCB1 and BCRP/ABCG2, increase the number of LDLR exposed on the BBB surface, thereby increasing doxorubicin-loaded nanoparticle entry across the BBB [39]; polyester-based nanoparticles loaded with paclitaxel improved BBB permeability in vitro [40]; and an infiltrative GBM preclinical model has been recently shown to be sensitive to enhanced proton treatment with LDLR-ligand peptide-conjugated gold nanoparticles [41]. Here, LDLR is linked to glioblastoma.